OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Key Takeaways Outlook Therapeutics stock sank after the FDA issued a third CRL rejecting the ONS-5010 BLA for wet AMD.OTLK's November 2025 resubmission was rejected for insufficient efficacy data, seeking confirmatory evidence.OTLK has secured EU and UK approval for Lytenava and launched the drug in Germany and the UK in 2025.Shares of Outlook Therapeutics (OTLK) have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third complete response letter (CRL) in late December, rejecti ...